Abstract: Provided herein in some embodiments are pharmaceutical compositions comprising a prostacyclin (PGI2) receptor agonist selected from 2-(((1r,4r)-4-(((4-chlorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetic acid (Compound 1) and pharmaceutically acceptable salts, solvates, and hydrates thereof, as disclosed herein. In some embodiments the pharmaceutical compositions comprise a compound selected from 2-(((1r,4r)-4-(((4-chlorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetic acid (Compound 1), and pharmaceutically acceptable salts, solvates, and hydrates thereof, in an amount equivalent to a therapeutically effective amount of Compound 1, the composition having a release rate by weight of the compound in an aqueous medium that is one or more of release rates (a), (b) and (c) as disclosed herein. The compositions of the present invention are useful in the treatment of PGI2 related disorders, such as those disclosed herein.

Abstract: This invention relates according to a solid cosmetic composition for makeup or treatment comprising: —a continuous fatty phase comprising at least one silicone polyamide, at least one non-volatile polar hydrocarbon-based oil and at least one polar wax of which the melting point is less than or equal to 90° C.; and—an aqueous phase dispersed in the continuous fatty phase, said silicone polyamide representing at most 9% by weight with respect to the total weight of said composition, and said wax representing at least 7% by weight with respect to the total weight of said composition.

Abstract: There is provided a convenient new treatment of Parkinson disease by a frequent administration of optimal levodopa doses mimicking a continuous intravenous or infusion treatment, thus mitigating motor complications; and a new carbidopa/levodopa pharmaceutical unit form providing said new treatment.

Abstract: Heterocyclic compounds are provided. In particular, the heteroatom of the heterocyclic compound may be nitrogen. The heterocyclic compounds may demonstrate capacity of stabilizing photoactive compounds. Topical compositions comprising these heterocyclic compounds are also provided. In particular, these topical compositions further comprise photoactive compounds. Methods for stabilizing photoactive compounds are also provided. These methods comprise mixing the photoactive compounds with photostabilizing heterocyclic compounds.

Abstract: A cosmetic composition includes, in a physiologically acceptable medium: at least water, at least alkylcellulose, at least one first hydrocarbon-based non-volatile oil, chosen from: C10-C26 alcohols, preferably monoalcohols; optionally hydroxylated monoesters, diesters or triesters of a C2-C8 monocarboxylic or polycarboxylic acid and of a C2-C8 alcohol; esters of a C2-C8 polyol and of one or more C2-C8 carboxylic acids. At least one second non-volatile oil chosen from silicone oils and/or fluoro oils or hydrocarbon-based oils other than the said first oil; at least one stabilizer chosen from surfactants and/or hydrophilic gelling agents, preferably chosen from associative polymers, natural polymers and their mixture.

Abstract: The present embodiments are directed to methods of using glycine transporter inhibitors, such as GlyT1 inhibitors, or pharmaceutically acceptable salts, solvates or prodrugs thereof, or pharmaceutical compositions thereof, for preventing or treating erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLPP), and/or congenital erythropoietic porphyria (CEP), and related syndromes thereof.

Abstract: Fatty acid-based, pre-cure-derived biomaterials, methods of making the biomaterials, and methods of using them as drug delivery carriers are described. The fatty acid-derived biomaterials can be utilized alone or in combination with a medical device for the release and local delivery of one or more therapeutic agents. Methods of forming and tailoring the properties of said biomaterials and methods of using said biomaterials for treating injury in a mammal are also provided.

Abstract: A film-based dosage form is provided. The dosage form includes a film base comprising a film-forming agent, a plasticizer and a solvent; and a matrix incorporated within the film base which comprises a target molecule that exhibits low aqueous solubility which is encapsulated and solubilized in a micellar formulation comprising a detergent in an aqueous solvent. The dosage form is particularly useful for administration of cannabinoids.

Abstract: Disclosed herein is a micro particle with a diameter of 10-100 microns, wherein the micro particle is coated with silver nanoparticles; and wherein the nanoparticles are coated with a polysaccharide; and wherein the polysaccharide coating is digestible by bacteria. Also, disclosed is a method of making silver nanoparticles using an ascorbic acid derivative or an alpha-hydroxyl carboxylic acid derivative as a reducing agent. The silver nanoparticles may be coated onto micro particles, embedded in hydrogel particles or coated with polysaccharide. The silver nanoparticles may be used in a wound dressing, a bandage, a fungal treatment product, a deodorant, a floss product, a toothpick, a dietary supplement, dental X-ray, a mouthwash, a toothpaste, acne or wound treatment product, skin scrub, and skin defoliate agent.

Abstract: The present invention provides methods for facilitating cleansing of the gastrointestinal tract of a patient prior to a diagnostic, surgical or therapeutic procedure. The methods can improve patient compliance, and thus, efficacy of the preparation. Specifically, the present methods make the gastrointestinal tract preparation composition palatable for the patient to consume. For example, for a patient preparing to undergo colonoscopy, the present methods make the bowel preparation solution taste significantly less salty.

Abstract: New nicotinic acid glycerol ester compound(s) (NAEs); topical personal care compositions containing NAEs; and methods for modulating or activating cellular AMPK levels; and for increasing skin cellular bioenergetics are described. Use of one or more of the nicotinic acid glycerol ester compounds for modulating or activating cellular AMPK levels; and for increasing skin cellular bioenergetics are described. Use of a skin benefit agent comprising certain nicotinic acid glycerol ester compounds in the manufacture of a topical personal care composition for modulating or activating cellular AMPK levels; and for increasing skin cellular bioenergetics are described.

Abstract: The present invention relates to novel nanoparticles using an anionic polymer, a preparation method thereof, a composition, and the like, and the present invention is used for a method of necrosing cancer cells by blocking major blood vessels that supply nutrients to cancer cells to induce an embolic effect, and thus may be used for the treatment of patients with cancer.

Abstract: Compositions comprising a mixture of at least two types of particles wherein a) the first type of particles comprise dabigatran etexilate in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates or hydrates thereof; and b) the second type of particles comprise at least one pharmaceutically acceptable organic acid, use of said compositions in the reduction of the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation and/or in the prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery and processes for the preparation of said compositions.

Abstract: The present invention provides methods of improve efficiency, growth, and performance in an animal by orally administering to the animal an effective amount of a therapeutic clay. The methods can reduce embryonic loss, increase litter size, increase the number of live births, improve the immune status of the maternal animal, reduce the concentration of maternal fecal amino acids, reduce the concentration of maternal fecal short-chained amino acid, increasing litter birth weight in the maternal animal, increase the amount of young animal colostrum intake, reduce young animal pre-weaning mortality, reduce the number of young animals lost due to low viability, reduce the number of weaned young animals, improve the immune status of young animals at weaning, reduce the number of lightweight young animals from nursery to market, increase the number of young animals marketed per sow, and increase calculated litter weight gain.

Abstract: A method of making infused non-demineralized cartilage particles employs the following steps: cutting or shaving cartilage tissue into cartilage particles, washing the particles, and infusing the particles with a supernatant of biologic material or a polyampholyte cryoprotectant or a combination of both to create infused particles.

Abstract: An antimicrobial wipe is provided including a textile comprised of natural fibers untreated with a chemical bonding agent, the textile is treated with an antimicrobial composition, the antimicrobial composition comprising a quaternary ammonium compound and an organic acid, wherein the antimicrobial composition is surfactant free, emollient free, and polymeric free. A method of preparing such wipes is also provided.

Abstract: Disclosed are compositions comprising Rhamnus prinoides (GESHO) extract or fragments thereof and methods of using Gesho extract for the inhibition of biofilm formation.

Abstract: Improved formulations of lipid nanoparticles are provided. Use of the lipid nanoparticles for delivery of a therapeutic agent and methods for their preparation are also provided.

Abstract: Modified plastic surfaces with perfluoropolymers are provided, whereby plastic surfaces that are intended for use under tribological conditions have substantially improved assembly properties and/or sliding friction properties and exhibit a very low degree of wear. Accordingly, modified plastic surfaces with perfluoropolymers are provided in which, after a reactive conversion under mechanical stress at room temperature, at least the reactive —NH groups and/or —OH groups present at the surface of plastics are present in a chemically covalently coupled manner with the perfluoropolymer carboxylic acid halide present at least in the surface-proximate region of modified perfluoropolymer (micro)powders and/or with the grafted (meth)acrylic acid halide present via perfluoropolymer (peroxy) radicals of the perfluoropolymer (micro)powders and/or (meth)acrylic acid that has been modified into (meth)acrylic acid halide before the reactive conversion.

Abstract: Dental pastes are provided which include: (i) a compound of Formula (I), (ii) a compound of Formula (II) or a pharmaceutically acceptable salt thereof, and (iii) a dental abrasive.